ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2862

Autoantigen Microarray Analysis Of Sera From New-Onset Pediatric Systemic Lupus Erythematosus Patients: A Distinct Autoantibody Profile Associated With Class III/IV Lupus Nephritis

Imelda Balboni1, David Haddon2, Vivian Diep2, Cindy Limb2 and Paul Utz2, 1Pediatrics, Stanford University School of Medicine, Palo Alto, CA, 2Medicine, Stanford University School of Medicine, Stanford, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: autoantibodies, Biomarkers, Nephritis, proteomics and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Pathogenesis and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous systemic autoimmune disease characterized by the production of autoantibodies directed against highly-conserved nuclear antigens. 15-20% of SLE patients develop disease in childhood or adolescence, and pediatric (pSLE) patients often have more severe disease onset and organ system involvement. Autoantigen microarray technology allows the comprehensive analysis of autoantibodies directed against hundreds of antigens with minimal amounts of sera. The purpose of this study was to characterize the spectrum of autoantibody reactivity in a cohort of new-onset pSLE patients and to identify an autoantibody profile that could serve as a biomarker for class III/IV lupus nephritis.

Methods: New-onset pediatric rheumatology patients meeting the revised ACR diagnostic criteria for SLE were eligible for this study. The study was approved by the Stanford University Institutional Review Board and informed consent was obtained prior to participation in the study. Demographic and clinical data at disease onset were collected. Sera from 51 pSLE patients and 20 healthy age- and sex-matched controls were evaluated using an 1128-feature antigen microarray manufactured with approximately 135 antigens. Microarrays were probed with 1:200 dilutions of serum and a Cy5-conjugated goat-anti-human IgG secondary antibody, scanned with a GenePix 4000 scanner, and analyzed using GenePix 6.1 software to determine median fluorescence intensity minus background for each antigen. Significance Analysis of Microarrays (SAM) software was used to determine differences in autoantibody reactivity between pSLE patients and controls, and between pSLE patients with and without proliferative nephritis. Enzyme-linked immunosorbant assays (ELISAs) were performed to confirm autoantibody reactivity identified by microarray.

Results: SAM identified increased reactivity against 50 autoantigens in sera from new-onset pSLE patients compared to controls, with a false discovery rate of zero. In addition to reactivity against classically-described SLE autoantigens, reactivity against several basement membrane and extracellular matrix proteins was identified. Subgroup analysis comparing patients with class III or IV Iupus nephritis to patients without significant nephritis demonstrated increased reactivity against several autoantigens including double-stranded DNA, C1q, histones, collagen and aggrecan in patients with proliferative nephritis. ELISAs confirmed a significant association between proliferative nephritis and reactivity against double-stranded DNA (p=0.0037), histones H2B (p=0.047) & H1 (p=0.02), C1q (p=0.0005), and type IV collagen (p=0.0051).

Conclusion: New-onset pSLE patients demonstrate a broad spectrum of autoantibodies directed against many autoantigens, including those not classically associated with SLE. Subgroup analysis of pSLE patients with and without nephritis revealed a distinct autoantibody profile that could serve as a biomarker for proliferative nephritis. We are currently developing a composite score, based on these autoantibodies and clinical data, to test on an additional cohort of pSLE patients.


Disclosure:

I. Balboni,
None;

D. Haddon,
None;

V. Diep,
None;

C. Limb,
None;

P. Utz,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/autoantigen-microarray-analysis-of-sera-from-new-onset-pediatric-systemic-lupus-erythematosus-patients-a-distinct-autoantibody-profile-associated-with-class-iiiiv-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology